Vimal Nanavati, MD
Interventional Cardiology · National City, CANPI 1851408082
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,905 of the $10,887 with a category attached, or 81.8%. 35 manufacturers reported payments, led by Cvrx, Inc. at 25.3% of the total.
Across 207 payments — averaging $52.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$3K
- Abbott$2K
- Penumbra, Inc.$1K
- Edwards Lifesciences$762
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$689
- Boston Scientific$620
- plus $3K from 29 others
Across 6 payments — averaging $1471.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$8K
- Boehringer Ingelheim International GmbH$431
What the payments were for
- Travel & lodging$1,98218%
- Food & beverage$8,90582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 41 | $2,757 |
| Abbott | 30 | $1,525 |
| Penumbra, Inc. | 5 | $1,150 |
| Edwards Lifesciences | 5 | $762 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $689 |
| Boston Scientific | 9 | $620 |
| Atricure, Inc. | 5 | $367 |
| Biotronik Inc. | 5 | $341 |
| Medtronic(2 entities) | 9 | $297 |
| Philips North America LLC | 20 | $274 |
| CMP Pharma, Inc. | 2 | $189 |
| Bayer | 3 | $184 |
| Amarin Pharma, Inc. | 4 | $178 |
| Abiomed | 3 | $172 |
| Bardy Diagnostics, Inc. | 3 | $162 |
| Amgen | 1 | $133 |
| AstraZeneca | 8 | $126 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Merck | 1 | $121 |
| GE HealthCare | 2 | $104 |
| Novartis | 6 | $101 |
| Venclose Inc. | 1 | $84 |
| Boehringer Ingelheim | 4 | $76 |
| Kestra Medical Technology Services, Inc. | 1 | $58 |
| Novo Nordisk | 2 | $43 |
| Shockwave Medical, Inc | 2 | $41 |
| Pfizer | 3 | $41 |
| Impulse Dynamics (USA) Inc. | 1 | $35 |
| Medicomp Inc | 1 | $31 |
| Davol Inc. | 1 | $25 |
| Cardinal Health 200 LLC | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Biomerieux Inc | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$1,905
- Indigo System$1,032
- Edwards SAPIEN 3 Transcatheter Heart Valve$762
- Quadra Assura CRT Defibrillator$310
- Watchman$294
- AVEIR$271
- VERQUVO$242
- Confirm Rx$180
- MitraClip$172
- Carospir$161
- LARIAT RS$160
- Kerendia$134
- KRYSTEXXA$133
- Carnation Ambulatory Monitor$125
- WATCHMAN Access System$125
- AJOVY$125
- Vascepa$120
- Impella$114
- BioMonitor$104
How this compares
$10,887 in reported general payments places this provider in the 55th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 45 | $46,498 |
| EliquisApixaban | 22 | $20,173 |
| XareltoRivaroxaban | 13 | $10,196 |
| Olmesartan Medoxomil | 43 | $883 |
| ClopidogrelClopidogrel Bisulfate | 42 | $856 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $494 |
| Metoprolol Succinate | 39 | $423 |
| Atorvastatin Calcium | 42 | $416 |
| Amiodarone Hcl | 21 | $360 |
| Ezetimibe | 25 | $353 |
| Midodrine Hcl | 16 | $296 |
| Carvedilol | 34 | $266 |
| Rosuvastatin Calcium | 26 | $225 |
| Metoprolol Tartrate | 18 | $157 |
| Lisinopril | 21 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $101 | $46,49845 claims |
| PfizerEliquis | $41 | $20,17322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in National City
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.